Entrada Therapeutics (TRDA) FCF Margin (2023 - 2026)
Entrada Therapeutics' (TRDA) quarterly FCF Margin came in at 4765.14% in Q1 2026, down 457731.0% year-on-year from N/an in Q1 2025, and down 91.5% quarter-over-quarter from 2488.38% in Q4 2025.
Entrada Therapeutics (TRDA) FCF Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 4765.14% for Q1 2026.
- On a quarterly basis, FCF Margin fell 457731.0% year-over-year to 4765.14% in Q1 2026; TTM through Mar 2026 was 2293.34%, a 225984.0% decrease from a year earlier, with the FY2025 full-year figure at 505.53%, down 48432.0% from the prior year.
- FCF Margin slipped to 4765.14% in Q1 2026 per TRDA's latest filing, from 2488.38% in the prior quarter.
- Across five years, FCF Margin topped out at 771.05% in Q1 2023 and bottomed at 4765.14% in Q1 2026.
- The 4-year median for FCF Margin is 103.92% (2024), against an average of 796.7%.
- Across the five-year window, FCF Margin jumped 19070 bps in 2024 and sank 457731 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 11.92% in 2023, then slumped by 726 bps to 98.42% in 2024, then plunged by 2428 bps to 2488.38% in 2025, then plunged by 91 bps to 4765.14% in 2026.
- Per Business Quant, the three latest TRDA FCF Margin figures stand at 4765.14% (Q1 2026), 2488.38% (Q4 2025), and 1751.98% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | -4,765.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,765.14% |
| Dec 31, 2025 | -2,488.38% |
| Sep 30, 2025 | -1,751.98% |
| Jun 30, 2025 | -1,502.36% |
| Mar 31, 2025 | -187.83% |
| Dec 31, 2024 | -98.42% |
| Sep 30, 2024 | -103.92% |
| Jun 30, 2024 | 40.20% |
| Mar 31, 2024 | -43.36% |
| Dec 31, 2023 | -11.92% |
| Sep 30, 2023 | -64.57% |
| Jun 30, 2023 | -150.51% |
| Mar 31, 2023 | 771.05% |